1:01 · January 19, 2024

About This Video

The contamination of Valsartan was caused by manufacturing defects, with the active ingredient being manufactured overseas in China and India. This led to the introduction of NDMA and large quantities of MDMA into the medication, which was 200 times the threshold amount for daily intake. China’s role in the Valsartan litigation highlighted the issue of cutting corners to save money, ultimately resulting in the contamination of the medication.